文献速递乳腺US

腋窝超声识别化疗后残留淋巴结病变:美国外科医师学会肿瘤学组Z1071试验(Alliance)结果

Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).
PubMed 文献 · AJR Am J Roentgenol · 2018-01-30

研究纳入611例初诊活检证实淋巴结阳性并接受新辅助化疗的乳腺癌患者,中央回顾化疗后腋窝超声图像,分析淋巴结大小、皮质厚度及皮质形态与手术病理残留淋巴结病变的关联。残留病变者373例(61.0%),皮质厚度增加、长短轴直径增大及脂肪门缺失与残留病变显著相关,形态I或II型残留率最低,VI型最高。

要点

  • 化疗后腋窝超声示皮质增厚、长短轴直径增大及脂肪门缺失与残留淋巴结病变显著相关。
  • 淋巴结形态VI型(完全低回声、无淋巴门)残留病变率最高(80.0%),I或II型最低(约56%)。
  • 腋窝超声可用于新辅助化疗后淋巴结反应评估。

核心结论

  • 新辅助化疗后腋窝超声有助于淋巴结反应评估,短轴直径长、长轴直径长、皮质厚度增加及脂肪门缺失与残留淋巴结病变显著相关。

研究设计与样本

  • 美国外科医师学会肿瘤学组Z1071试验(Alliance)的影像学分析,共611例初诊活检证实淋巴结阳性乳腺癌患者,均在新辅助化疗后行腋窝超声,图像中央回顾,以最终手术病理为参考标准。

关键影像表现/征象

  • 皮质厚度增加与残留淋巴结病变相关:淋巴结阳性病变平均3.5 mm vs 淋巴结阴性病变平均2.5 mm。
  • 淋巴结短轴和长轴直径与病理结果显著相关。
  • 残留淋巴结病变率在形态I型为51/91例(56.0%)、II型为138/246例(56.1%)、VI型为44/55例(80.0%)(p=0.004)。
  • 脂肪门存在与淋巴结阴性病变显著相关(p=0.0013)。

诊断标准与关键数值

  • 皮质形态分型:I型为未见可见皮质;II型为低回声皮质≤3 mm;III型为低回声皮质>3 mm;IV型为弥漫性分叶状低回声皮质;V型为局灶性低回声皮质分叶;VI型为完全低回声淋巴结、无淋巴门。

临床应用与阅片要点

  • 阅片时关注化疗后腋窝淋巴结的短轴直径、长轴直径、皮质厚度及脂肪门是否缺失,这些特征与残留淋巴结病变相关。
  • 注意形态VI型(完全低回声、无淋巴门)残留病变率最高(80.0%),形态I或II型残留率最低(约56%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The purpose of this study is to determine lymph node features on axillary ultrasound (US) images obtained after neoadjuvant chemotherapy that are associated with residual nodal disease in patients with initial biopsy-proven node-positive breast cancer.

SUBJECTS AND METHODS: All patients had axillary US performed after neoadjuvant chemotherapy. Axillary US images were centrally reviewed for lymph node size, cortical thickness, and cortical morphologic findings (type I indicated no visible cortex; type II, a hypoechoic cortex ≤ 3 mm; type III, a hypoechoic cortex > 3 mm; type IV, a generalized lobulated hypoechoic cortex; type V, focal hypoechoic cortical lobulation; and type VI, a totally hypoechoic node with no hilum). Lymph node characteristics were compared with final surgical pathologic findings.

RESULTS: Axillary US images obtained after neoadjuvant chemotherapy and surgical pathologic findings were available for 611 patients. Residual nodal disease was present in 373 patients (61.0%), and 238 (39.0%) had a complete nodal pathologic response. Increased cortical thickness (mean, 3.5 mm for node-positive disease vs 2.5 mm for node-negative disease) was associated with residual nodal disease. Lymph node short-axis and long-axis diameters were significantly associated with pathologic findings. Patients with nodal morphologic type I or II had the lowest rate of residual nodal disease (51 of 91 patients [56.0%] and 138 of 246 patients (56.1%), respectively), whereas those with nodal morphologic type VI had the highest rate (44 of 55 patients [80.0%]) (p = 0.004). The presence of fatty hilum was significantly associated with node-negative disease (p = 0.0013).

CONCLUSION: Axillary US performed after neoadjuvant chemotherapy is useful for nodal response assessment, with longer short-axis diameter, longer long-axis diameter, increased cortical thickness, and absence of fatty hilum significantly associated with residual nodal disease after neoadjuvant chemotherapy.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Le-Petross HT, McCall LM, Hunt KK, et al. Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). AJR Am J Roentgenol. 2018. PMID: 29381381. doi:10.2214/AJR.17.18295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。